Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRVI Trevi Therapeutics, Inc.

Closed 07-02 16:00:00 EDT

17.93

+0.32

+1.82%

盘后17.93

+0.000.00%

17:14 EDT

High18.25	Low17.51	Vol2.21M
Open17.73	D1 Closing17.61	Amplitude4.20%
Mkt Cap2.55B	Tradable Cap2.08B	Total Shares142.00M
T/O39.52M	T/O Rate1.90%	Tradable Shares116.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TRVI","market":"US","secType":"STK","nameCN":"Trevi Therapeutics, Inc.","latestPrice":17.93,"timestamp":1783022400000,"preClose":17.61,"halted":0,"volume":2206588,"hourTrading":{"tag":"盘后","latestPrice":17.93,"preClose":17.93,"latestTime":"17:14 EDT","volume":52696,"amount":944845.43,"timestamp":1783026855268,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.018171493469619552,"floatShares":115999999,"shares":142000000,"eps":-0.321787,"marketStatus":"Closed","change":0.32,"latestTime":"07-02 16:00:00 EDT","open":17.73,"high":18.25,"low":17.51,"amount":39517607.964959994,"amplitude":0.042022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.321787,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1557201600000,"exchange":"NASDAQ","adjPreClose":17.61,"preHourTrading":{"tag":"盘前","latestPrice":17.7225,"preClose":17.61,"latestTime":"07:33 EDT","volume":14,"amount":246.156498,"timestamp":1782992021555,"change":0.1125,"changeRate":0.006388,"amplitude":0.031175},"postHourTrading":{"tag":"盘后","latestPrice":17.93,"preClose":17.93,"latestTime":"17:14 EDT","volume":52696,"amount":944845.43,"timestamp":1783026855268,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.564595,"impliedVol":0.5015,"impliedVolPercentile":0.494},"requestUrl":"/m/hq/s/TRVI","defaultTab":"news","newsList":[{"id":"2644439777","title":"Trevi Therapeutics management attends BIO International Convention in June and July events","url":"https://stock-news.laohu8.com/highlight/detail?id=2644439777","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644439777?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:30","pubTimestamp":1781695856,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics management plans to attend the BIO International Convention on June 22-25, 2026 in San Diego.The company is also scheduled for the Leerink Partners Therapeutics Forum on July 14-15, 2026 in Boston.Trevi is set to attend the ERS Cough Conference on July 15-17, 2026 in London.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL3pnHTc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","SG9999014005.SGD","TRVI","BK4588","IE00BN0W2V16.EUR","BK4112","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014021.USD","MNSH","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","BK4007","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641162306","title":"Trevi Therapeutics shareholders approve increase in authorized common shares to 400 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2641162306","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641162306?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:08","pubTimestamp":1780603722,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics held its annual shareholder meeting on June 3, 2026.Investors adopted an amended and restated 2019 stock incentive plan, lifting the share reserve by 8 million shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL1NZMVs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147932153","title":"Stock Track | Trevi Therapeutics Soars 5.27% in Intraday Trading After Stifel Raises Target Price to $30","url":"https://stock-news.laohu8.com/highlight/detail?id=1147932153","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147932153?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:35","pubTimestamp":1778247306,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics, Inc. (TRVI) saw its stock price soar by 5.27% during intraday trading on Friday, reflecting a significant positive market reaction.The surge appears to be driven by bullish...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633517744","title":"Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633517744","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633517744?lang=en_us&edition=fundamental","pubTime":"2026-05-08 21:10","pubTimestamp":1778245853,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI), Joint (JYNT) and Immunity...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-joint-jynt-and-immunitybio-ibrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-trevi-therapeutics-trvi-joint-jynt-and-immunitybio-ibrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRVI","BK4185","BK4585","BK4588","LABU","XBI","BK4137","IBRX","HCSG","BK4581","LU0029874061.USD","LU0128526141.USD","JYNT","BK4139","XLV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131687373","title":"Stock Track | Trevi Therapeutics Plummets 5.39% Intraday on Q1 Loss Worse Than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=1131687373","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131687373?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:29","pubTimestamp":1778077773,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics, Inc. (TRVI) saw its stock price plummet 5.39% during intraday trading on Wednesday, following the release of its first-quarter financial results.The company reported a Q1 loss of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633181926","title":"Morgan Stanley Remains a Buy on Trevi Therapeutics (TRVI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633181926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633181926?lang=en_us&edition=fundamental","pubTime":"2026-05-06 18:33","pubTimestamp":1778063602,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer maintained a Buy rating on Trevi Therapeutics yesterday and set a price target of $20.00. According to TipRank...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-trevi-therapeutics-trvi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-trevi-therapeutics-trvi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0225283273.USD","LU1363072403.SGD","LU2264538146.SGD","LU1732799900.SGD","LU0528227936.USD","LU1074936037.SGD","LU0795875086.SGD","LU1989772923.USD","LU0557290698.USD","LU2271345857.HKD","LU2347655156.SGD","LU2089284900.SGD","LU0234570918.USD","BK4007","LU1989772840.SGD","BK4516","LU0267386448.USD","BK4127","LU0006306889.USD","LU0158827781.USD","LU1244550494.USD","LU1548497426.USD","LU0158827948.USD","LU0912757837.SGD","BK4534","LU1720051108.HKD","LU1791710400.SGD","TRVI","LU0098860793.USD","LU1988902786.USD","LU0106831901.USD","LU0314104364.USD","BK4504","IE00BZ1G4Q59.USD","LU1064131342.USD","LU1244550221.USD","LU0106261372.USD","LU0320765646.SGD","LU1668664300.SGD","BK4581","BK4585","IE00BKVL7J92.USD","LU0795875169.SGD","LU1791710582.SGD","LU2089283258.USD","LU2133065610.SGD","LU1162221912.USD","LU2357305700.SGD","LU2023251221.USD","LU1720051017.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633907434","title":"Trevi Therapeutics Q1 Loss Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2633907434","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633907434?lang=en_us&edition=fundamental","pubTime":"2026-05-06 16:29","pubTimestamp":1778056187,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics (TRVI) reported a Q1 loss late Tuesday of $0.09 per diluted share, in-line a year earlier.Analysts polled by FactSet expected a loss of $0.08.The company ended the quarter with $1718 million in cash, cash equivalents and marketable securities, providing a cash runway into 2030.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TRVI","BK4139","BK4539","LENZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633922912","title":"Trevi Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633922912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633922912?lang=en_us&edition=fundamental","pubTime":"2026-05-06 05:01","pubTimestamp":1778014887,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryTrevi Therapeutics Inc TRVI.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I3FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924069","title":"Trevi Therapeutics Q1 net loss widens as R&D costs rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924069","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924069?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:53","pubTimestamp":1778014402,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics Q1 net loss widens as R&D costs riseOverviewU.S. biopharma firm's Q1 net loss widened as R&D and G&A expenses increasedCompany completed $162 mln stock offering, extending expected ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL1N41I1C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633926889","title":"BRIEF-Trevi Therapeutics Q1 Net Income USD -13.192 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633926889","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633926889?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011548,"startTime":"0","endTime":"0","summary":"BRIEF-Trevi Therapeutics Q1 Net Income USD -13.192 Million\n\n\nMay 05 (Reuters) - Trevi Therapeutics Q1 operating expenses USD 14.912 million.\n\nQ1 income from operations USD -14.912 million\nQ1 EPS USD -0.09\nQ1 pretax profit USD -13.212 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLXD05006:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633192574","title":"Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633192574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633192574?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011505,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUA4M7JBC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633925209","title":"Trevi Therapeutics Q1 EPS USD -0.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2633925209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633925209?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:05","pubTimestamp":1778011505,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nPLXD05006:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632543669","title":"Trevi Therapeutics to present Phase 2b CORAL nalbuphine ER data at ATS conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2632543669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632543669?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:28","pubTimestamp":1777580916,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics will deliver an oral presentation at American Thoracic Society 2026 International Conference in Orlando, Florida on May 18.Multiple posters on nalbuphine ER data are scheduled during ATS 2026 sessions on May 17-19.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL86n3VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014013.SGD","BK4007","LU0314104364.USD","LU2095319765.USD","BK4112","IE00BN0W2W23.USD","TRVI","SG9999014039.USD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","LU2210150020.SGD","NDAQ","SG9999014021.USD","BK4588","IE00B3QW5Z07.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632665919","title":"Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2632665919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632665919?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579507,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA3JNX06:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631353585","title":"Trevi Therapeutics to report Q1 results, host corporate update call May 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2631353585","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631353585?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:12","pubTimestamp":1777407148,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics schedules first-quarter 2026 financial results release on May 5, 2026.Management hosts conference call on May 5, 2026 at 4:30 p.m. ET to provide corporate update.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL13ngys:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014039.USD","LU2210150020.SGD","TRVI","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","BK4007","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2W23.USD","BK4588","IE00BN0W2T93.GBP","BK4112","LU2095319765.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631533356","title":"Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631533356","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631533356?lang=en_us&edition=fundamental","pubTime":"2026-04-29 04:05","pubTimestamp":1777406700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nTUA2Z9M3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRVI","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630588710","title":"Why Trevi Therapeutics (TRVI) Is Down 7.3% After $150.8M Equity Raise And Share Authorization Boost","url":"https://stock-news.laohu8.com/highlight/detail?id=2630588710","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630588710?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:11","pubTimestamp":1777381867,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics recently completed a US$150.8 million follow-on equity offering of 11,600,000 common shares at US$13 each, and separately proposed amending its certificate of incorporation to double its authorized common stock to 400,000,000 shares. \nThis combination of fresh capital and a large increase in authorized shares materially expands Trevi’s flexibility to fund future corporate and clinical objectives without repeatedly returning to shareholders for approval. \nWe’ll now examine...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/why-trevi-therapeutics-trvi-is-down-73-after-1508m-equity-ra","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-trvi/trevi-therapeutics/news/why-trevi-therapeutics-trvi-is-down-73-after-1508m-equity-ra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4215","EQR","BK4588","BK4007","TRVI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629486856","title":"Trevi Therapeutics to host investor and analyst day in May","url":"https://stock-news.laohu8.com/highlight/detail?id=2629486856","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629486856?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:11","pubTimestamp":1776975104,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics will host an Investor and Analyst Day on May 7, 2026, in Midtown New York.Management will present at Bank of America Global Healthcare Conference on May 12, 2026, in Las Vegas.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL8MsXXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BN0W2T93.GBP","TRVI","IE00B3QW5Z07.USD","NDAQ","BK4112","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","BK4007","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629450706","title":"Trevi Therapeutics Inc : Leerink Partners Raises Target Price to $25 From $21","url":"https://stock-news.laohu8.com/highlight/detail?id=2629450706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629450706?lang=en_us&edition=fundamental","pubTime":"2026-04-21 11:13","pubTimestamp":1776741196,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN4130NU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629777548","title":"Trevi Therapeutics closes USD 173 million follow-on stock offering at USD 13 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2629777548","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629777548?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:05","pubTimestamp":1776715544,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics closed underwritten public offering of 13,340,000 common shares at USD 13 per share.Gross proceeds were about USD 173 million before underwriting discounts, commissions, and offering expenses.Underwriters exercised option in full to buy 1,740,000 additional shares.All shares in offering were sold by Trevi.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDLbSm55B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4112","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","TRVI","SG9999014039.USD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4588","BK4585","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","BK4007","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.trevitherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.2624},{"period":"3month","weight":0.4749},{"period":"6month","weight":0.4811},{"period":"1year","weight":2.0895},{"period":"ytd","weight":0.4065}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.062028},{"month":2,"riseRate":0.857143,"avgChangeRate":0.194268},{"month":3,"riseRate":0.571429,"avgChangeRate":0.340057},{"month":4,"riseRate":0.571429,"avgChangeRate":0.129333},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.1063},{"month":6,"riseRate":0.75,"avgChangeRate":0.224365},{"month":7,"riseRate":0.375,"avgChangeRate":-0.018628},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.078417},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065787},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.063981},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.046063},{"month":12,"riseRate":0.571429,"avgChangeRate":0.034671}],"exchange":"NASDAQ","name":"Trevi Therapeutics, Inc.","nameEN":"Trevi Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Trevi Therapeutics, Inc.,TRVI,Trevi Therapeutics, Inc.股票,Trevi Therapeutics, Inc.股票老虎,Trevi Therapeutics, Inc.股票老虎国际,Trevi Therapeutics, Inc.行情,Trevi Therapeutics, Inc.股票行情,Trevi Therapeutics, Inc.股价,Trevi Therapeutics, Inc.股市,Trevi Therapeutics, Inc.股票价格,Trevi Therapeutics, Inc.股票交易,Trevi Therapeutics, Inc.股票购买,Trevi Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Trevi Therapeutics, Inc.(TRVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Trevi Therapeutics, Inc.(TRVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction